Log inSign up
AAOIFI No. 21 screening

Is AKTS halal?

Aktis Oncology, Inc.

Not halal

Aktis Oncology, Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 15 October 2026

Exchange

NASDAQ

Price

15.06

Day

-5.93%

Market cap

$911.6M

Industry

Biotechnology

Sector

Healthcare

What the company does

Aktis Oncology develops targeted radiopharmaceuticals for solid tumors (molecules that deliver a radioactive payload to cancer cells, targeting Nectin-4 and B7-H3), in Phase 1b trials. Funded by an Eli Lilly partnership and investors; no product revenue.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ current market cap $911.60M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $517.32M ÷ current market cap $911.60M = 56.8%

    56.8%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    Interest income $11.01M ÷ annual revenue $6.50M (2025) = 169.4%

    169.4%

    Fail

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict.

In the lists

In the S&P 500
Not in the S&P 500

Superinvestors

SEC 13F, 2026 Q3. Up to 45 days delayed.

Held by 1 superinvestors · Average reported price: $32.23

All superinvestor portfolios

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyAKTS's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →